anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tuberculosis (TB) is a major fatal infectious disease globally, exhibiting high morbidity rates and impacting public health and other socio-economic factors. However, some individuals are resistant to TB infection and are referred to as "Resisters". Resisters remain uninfected even after exposure to high load of Mycobacterium tuberculosis (Mtb). To delineate this further, this study aimed to investigate the factors and mechanisms influencing the Mtb resistance phenotype. We assayed the phagocytic capacity of peripheral blood mononuclear cells (PBMCs) collected from Resisters, patients with latent TB infection (LTBI), and patients with active TB (ATB), following infection with fluorescent Mycobacterium bovis Bacillus Calmette-Guérin (BCG). Phagocytosis was stronger in PBMCs from ATB patients, and comparable in LTBI patients and Resisters. Subsequently, phagocytes were isolated and subjected to whole transcriptome sequencing and small RNA sequencing to analyze transcriptional expression profiles and identify potential targets associated with the resistance phenotype. The results revealed that a total of 277 mRNAs, 589 long non-coding RNAs, 523 circular RNAs, and 35 microRNAs were differentially expressed in Resisters and LTBI patients. Further, the endogenous competitive RNA (ceRNA) network was constructed from differentially expressed genes after screening. Bioinformatics, statistical analysis, and quantitative real-time polymerase chain reaction were used for the identification and validation of potential crucial targets in the ceRNA network. As a result, we obtained a ceRNA network that contributes to the resistance phenotype. TCONS_00034796-F3, ENST00000629441-DDX43, hsa-ATAD3A_0003-CYP17A1, and XR_932996.2-CERS1 may be crucial association pairs for resistance to TB infection. Overall, this study demonstrated that the phagocytic capacity of PBMCs was not a determinant of the resistance phenotype and that some non-coding RNAs could be involved in the natural resistance to TB infection through a ceRNA mechanism.
Participants who had been diagnosed with knee osteoarthritis according to American College of Rheumatology (ACR) criteria will be enrolled in this study. After the participants receive the information and consent to participate in this study, they will be examined their affected knee by the co-researchers. Ten-milligrams of Triamcinolone will be injected intra-articular into knee joint.

Two-to-four weeks later, the participants will be evaluated for knee pain, stiffness, function and quality of life, as well as knee performance status. Participants whose their knee joint absence of effusion will be allocated in to one treatment group; either Hyaluronic acid or normal saline. After injection, participants will be scheduled for the follow-up visit in 12 and 24 weeks later. In each follow-up visit, they will be evaluated for joint pain, stiffness, function and quality of life, as well as analgesic use and adverse reaction form treatment.
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet and Cognitive Decline in Middle-aged and Elderly People is a 12-month cluster-randomized controlled trial designed to test the effect of the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet education on the rate of cognitive change and several other secondary outcomes in 1200 adults aged 40-69 years. The proposed MIND diet for this study is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet-dementia field and Chinese Dietary Guidelines 2022. Specifically, the proposed MIND diet education will emphasize the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafood, beans and legumes, nuts, olive and seed oils, and green tea, and restrict red and processed meats, animal fat, fried foods, and sweets and pastries. The trial will employ a cluster randomization design comparing the effects on cognitive change of the MIND intervention diet education among 1200 adults aged 40-69 years. Secondary outcomes will include dietary behavior changes, health status changes, etc. The proposed study is sited at Taian, Shandong, China.
FIELD: medicine, biology. SUBSTANCE: invention relates to preparations stimulating DNA synthesis. Invention proposes the use of β-form of methyluracil as stimulating agent of endogenic DNA synthesis. This use can be used at all cases of DNA damage (effect of radiation, intoxication with cytostatics and others). EFFECT: enhanced effectiveness of stimulation. 1 tbl
Follicular lymphoma (FL) is a common type of B-cell lymphoma, accounting for about 20% of all lymphomas. Although FL is primarily characterized by an indolent clinical course, histological transformation (HT) remains one of the significant challenges in managing patients with FL. Here, we present a case of FL with partial large-cell transformation due to Epstein-Barr Virus (EBV) arising in a 50-year-old Japanese woman with no known immunodeficiency. Immunohistochemical studies revealed that medium-sized FL cells expressed CD20, CD10, BCL2, and BCL6, whereas large cells were positive for CD20, and MUM1. In situ hybridization (ISH) revealed large cells to be positive for EBV-encoded small RNA (EBER) and further immunohistochemical investigation demonstrated EBER+ cells to express latent membrane protein 1 (LMP1). The Ki-67 index was about 30% in FL cells, and over 70% in large cells. Fluorescence in situ hybridization for BCL2 combined with EBER-ISH identified BCL2 rearrangement in both EBV-infected large cells and EBV-uninfected FL cells, suggesting these two components were clonally related. These findings indicate that EBV contributes to the transformation of FL. As far as the authors could find, only four previous cases of FL development to EBV-positive aggressive lymphoma have been reported. Further studies are needed to clarify the role of EBV in the HT of FL.
Polyphenols may have several favourable effects on health. Dark chocolate (DC) is one of the highest sources of polyphenols in foods. The aim of the study is to determine the effect of polyphenol-rich dark chocolate on insulin sensitivity in normal weight and overweight adults. Seventy four volunteers with no history of hypertension, cardiovascular diseases or diabetes will be recruited. Participants will randomly receive 20g daily of one of the two different types of DC: Placebo DC (low in polyphenols) or DC rich in polyphenols (500mg) for a period of four weeks. Participants will be asked to make two appointments to the university clinical lab. Anthropometric measurements (height, weight, waist circumference), blood and saliva samples will be taken during each of the 2 visits. Compliance will be tested by the measure of total polyphenols in a 24-hour urine sample in some random samples before and at the end of the intervention. To monitor any fluctuations in the participants' diet or physical activity during the study period, a three-day diet diary and a physical activity questionnaire will be collected before the start of the study and after four weeks. Data will be analysed with an ANCOVA with time (pre- and post-) and treatment (DC and placebo) as between-subject factor.
Enrollment into the Late Pre-IMAT Cohort will begin one year prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
Four weekly group lifestyle education sessions of a 1.5-hour duration. Homework consisting of reading, diet monitoring, stretching/toning exercises, and brainstorming new healthy living techniques/ideas.
Squill is macerated with a water-miscible organic solvent such as denatured alcohol, the solution is evaporated and the residue dissolved in water.  The aqueous solution is agitated with an organic solvent not miscible with water, e.g. petroleum ether, to dissolve out scillin, fats and oils.  The active principles are precipitated from the purified aqueous solution with tannic acid, a salt such as sodium chloride being added to complete the precipitation.  The precipitated tannates are decomposed with an inorganic oxide or hydroxide such as zinc oxide.  The product is separated into three distinct cardio-active substances by the following procedure.  The aqueous solution of the product is agitated with a solvent such as absolute ethyl acetate which dissolves principles I and II. Principle III is recovered from the aqueous solution by precipitation with tannic acid, decomposition of the tannate with a metallic oxide, and recrystallization of the product from absolute ethyl alcohol. The solution of principles I and II is evaporated, redissolved in chloroform, and agitated with dilute aqueous alkaline carbonate solution which dissolves principle II.  This solution is neutralized and treated with a non-miscible solvent such as ethyl acetate from which principle II is obtained by evaporation.  The chloroform solution of principle I is evaporated and the product recrystallized from ethyl acetate.  The combustion analysis and physical properties of the three principles are described.  They are all readily hydrolyzed, producing aglycones.ALSO:Squill is macerated with a water-miscible organic solvent such as denatured alcohol, the solution is evaporated and the residue dissolved in water.  The aqueous solution is agitated with an organic solvent not miscible with water, e.g. petroleum ether, to dissolve out scillin, fats, and oils.  The active principles are precipitated from the purified aqueous solution with tannic acid, a salt such as sodium chloride being added to complete the precipitation.  The precipitated tannates are decomposed with an inorganic oxide or hydroxide such as zinc oxide.  The product is separated into three distinct cardio-active substances by the following procedure.  The aqueous solution of the product is agitated with a solvent such as absolute ethyl acetate which dissolves principles I and II.  Principle III is recovered from the aqueous solution by precipitation with tannic acid, decomposition of the tannate with a metallic oxide, and recrystallization of the product from absolute ethyl alcohol.  The solution of principles I and II is evaporated, redissolved in chloroform, and agitated with dilute aqueous alkaline carbonate solution which dissolves principle II.  This solution is neutralized and treated with a non-miscible solvent such as ethyl p  acetate from which principle II is obtained by evaporation.  The chloroform solution of principle I is evaporated and the product recrystallized from ethyl acetate.  The combustion analysis and physical properties of the three principles are described.  They are all readily hydrolyzed, producing aglycones.
Selective nerve transfers provide an opportunity for restoring the motor function after nerve injuries. Over the past decade different hand rehabilitation protocols and exercises are developed, robotic assisted rehabilitation is one of them. Upper-limb robot-assisted therapy has been established as a safe and feasible treatment to complement rehabilitation after neurological injury. Robots can precisely control the interaction with the user (e.g., supporting or resisting in an assist-as-needed manner) and render virtual environments both visually and mechanically, making them ideal tools for sensorimotor training, providing engaging and challenging therapy. The aim of this study is to explore the combined effects of Hand Training with Robotic Glove on fine and gross motor function and activities of daily living in patients after median nerve transfer. The study will be randomized controlled trial. Participants will be recruited through non probability convenience sampling technique. After screening for eligibility, participants will be randomly assigned by balanced pre-randomization into two groups either to a robot-assisted group (RG), participants of this group receiving robot-assisted Hand Rehabilitation with Syrebo Robotic Gloves or to a control group (CG), receiving dose-matched conventional Hand Rehabilitation without the robot. The participants will be engaged in exercises 4 times a week for 6 weeks, each participants will receive three Hand Rehabilitation therapy sessions per day focusing on hand function. Each therapy session will be of 45 minutes. These sessions will be embedded in the weekly therapy plan for each individual participant. Data will be assessed at the start of the 1st session and at the end of the last session after 6 weeks with the help of Sollerman Hand Function test, Jebsen Taylor Hand Function test, The Original Barthel Index for Activities of Daily living. Data will be analyzed using SPSS version 25. Key words: Hand Rehabilitation, Nerve transfer Rehabilitation, Robotic Glove
AML is a malignant disease of myeloid hematopoietic stem / progenitor cells and the most common hematological malignancy. It is characterized by abnormal proliferation of primitive and immature myeloid cells in bone marrow and peripheral blood. In recent years, due to the aging of the population, the incidence of AML and MDS has been on the rise. What is also troubling us is that the incidence of treatment-related MDS and AML in children and adolescents with Hodgkin's disease, sarcoma, breast and testicular tumors, lymphoma and other patients who survive after treatment is also gradually increasing. Occupational exposure such as ionizing radiation and benzene and petrochemical are also related to the incidence of AML.

Car t therapy is the most effective and widely used in the treatment of all. B7-H3, also known as cd276, was first discovered in 2001. It is mainly expressed on the cell surface, such as activated dendritic cells, monocytes, T cells, B cells and NK cells. Studies have shown that B7-H3 can stimulate the expansion and killing of T cells, and may selectively stimulate the signal receptor of T cells. It is a promising target for AML immunotherapy.
BACKGROUND AND AIMS: Atherosclerotic cardiovascular disease complicated by diabetes mellitus (DM) is the leading cause of death in diabetic patients, and it is strongly associated with macrophages and inflammasomes. It has been found that activation of NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome is closely associated with phosphatidylinositol 4-phosphate (PI4P) on the trans-Golgi. However, how PI4P and NLRP3 regulate macrophage function and its role in diabetic atherosclerotic plaques is unclear.
METHODS: The expression of Pi4p and Nlrp3-inflammasome-related proteins in atherosclerosis in apolipoprotein E-deficient (Apoe-/-) and Apoe-/- DM mice was investigated. Then, Pi4p levels were affected by shRNA-Pi4kb or cDNA-Sac1 plasmid to investigate the effects of changes in Pi4p-related metabolic enzymes on macrophage function. Finally, genetically modified macrophages were injected into diabetic Apoe-/- mice to explore the effects on atherosclerosis.
RESULTS: DM promoted plaque progression in atherosclerotic mice and increased expression of Pi4p and Nlrp3 in plaques. In addition, impaired macrophage function induced by high glucose was reversed by transfected shRNA-Pi4kb or cDNA-Sac1 plasmid. Furthermore, decreased levels of Pi4p reduced plaque area in diabetic Apoe-/- mice.
CONCLUSIONS: Our data suggests that Pi4p/Nlrp3 in macrophages play an important role in the exacerbation of atherosclerosis in diabetic mice. Pi4p-related metabolizing enzymes (PI4KB and SAC1) may be a potential therapeutic strategy for diabetic atherosclerosis, and macrophage therapy is also a potential treatment.
The invention discloses a traditional Chinese medicinal composition used for improving hybridization capability of a ram as well a preparation method and an application thereof. The invention firstly discloses a traditional Chinese medicinal composition used for improving the hybridization capability of the ram. The traditional Chinese medicinal composition comprises skyblue broomrape herb, epimedium, cortex acanthopanacis and gallnut. On the basis of the traditional Chinese medicinal composition disclosed by the invention, raw materials, namely rhizoma sparganii and rhizoma acori graminei, are added, or the raw materials, namely asarum and kudzuvine root, are added, so that better effects of tonifying kidney yang and benefiting essence and blood are realized. Animal experiments prove that the raw materials, namely skyblue broomrape herb, epimedium, cortex acanthopanacis and gallnut, are obviously synergistic with the raw materials, namely rhizoma sparganii and rhizoma acori graminei, and also obviously synergistic with the raw materials asarum and kudzuvine root, and all the raw materials can respectively obviously improve average single ejaculate volume, sperm vitality and sperm density of the ram and pregnancy rate of an ewe. The traditional Chinese medicinal composition disclosed by the invention is reasonable in compatibility and simple in the preparation method and can be applied to preparation of a medicine used for treating improving hybridization capability of the ram.
Juggling is a form of exercise, that can engage humans, both cognitively and physically. One of the positive aspects of taking up this form of exercise is the growing evidence indicating that juggling improves the well-being of exercisers. Most importantly, the juggling intervention causes an increase in the volume of the gray matter and white matter in the human brain, and thus shows potential for neuroplasticity. In addition, unhealthy aging is observed nowadays, which causes both physical and cognitive decline in daily functioning, further interfering with the elderly's ability to perform daily activities. Therefore, the addition of juggling exercises may have a positive effect on the changes that occur with aging.

However, currently there are hardly any data on the juggling effect on cognitive functions and on postural stability. Therefore, the study aims to examine the effect of juggling exercises on selected cognitive functions and postural stability variables in two different randomised trials.
OBJECTIVE: Enhanced recovery after surgery (ERAS) was developed as a way to standardize clinical care pathways and communication across multidisciplinary teams to improve patient recovery and reduce hospital length of stay (LOS). Our objective was to implement an ERAS protocol for cesarean delivery (ERAS-CD) and evaluate its efficacy in reducing LOS.
STUDY DESIGN: An ERAS-CD program was implemented at our institution in October 2018. Patients undergoing scheduled and unscheduled CD were maintained on an ERAS pathway of care, which included preoperative hydration, standardized intraoperative protocols, and postoperative analgesic regimens as well as early feeding, urinary catheter removal, and ambulation. We compared LOS after delivery (calculated from time of delivery to discharge), readmission rates, health care disparities and postoperative opioid prescribing practices before (October 2017-September 2018) and after (November 2018-October 2019) ERAS implementation. We excluded any outliers, defined as a LOS >25 days. Continuous data are expressed as mean ± standard deviation. Student's t-test and Chi-square were used for statistical comparison with p <0.05 considered statistically significant.
RESULTS: There were 1,729 patients who had a CD in the pre-ERAS group with a mean LOS after delivery of 3.32 ± 6.19 days. In the post-ERAS group, 1,753 women underwent CD with a mean LOS after delivery of 2.85 ± 5.79 days, a statistically significant difference from the pre-ERAS group (p <0.001). There was no difference in readmission rates between pre- and post-ERAS implementation groups (1.9 vs. 2.2%, p = 0.53). There was a reduction in health care disparities in postoperative LOS, when stratifying by race-ethnicity, and a reduction in opioid prescribing practices after the implementation of the program.
CONCLUSION: With the implementation of an ERAS-CD program, we achieved a reduced LOS, without increasing readmission rates, and saw a reduction in health care disparities and opioid dispensing. A shorter LOS could offer an enhanced patient experience, as well as improved and equitable perioperative outcomes.
KEY POINTS: · ERAS-CD is associated with a reduction in postoperative hospital length of stay.. · A reduction in health care disparities by race-ethnicity was observed with the implementation of ERAS-CD.. · A reduction in opioid dispensing was observed with the implementation of ERAS-CD..
The invention belongs to the technical field of bioengineering, and relates to a polypeptide with an anti-wrinkle function, a compound and application thereof. The invention provides a polypeptide with an anti-wrinkle function, and the amino acid sequence of the polypeptide is shown as SEQ ID No. 1; the SEQ ID No.1 is: CEFMRNEFEEMQRR. The present invention provides a complex comprising the polypeptide, which comprises the polypeptide having anti-wrinkle function, HAuCl  4  Vitamin C ascorbic acid. The invention also provides application of the compound in preparation of cosmetics, wherein the cosmetics comprise any one of eye cream, face cream, essence and facial mask. The polypeptide with anti-wrinkle function and the compound thereof provided by the invention have good stability, affinity and permeability, and show good biocompatibility, and are used for facial expression muscle paralysis relaxation, so as to improve facial contour and eliminate or reduce wrinklesIs effective in treating the disease.
Systems and methods for providing a health care service provider specific wireless access point that facilitates secure communication between a patient, provider, and/or third-party service. Patient devices may connect to the healthcare service provider (HSP) wireless access point or “hub” when they are in range of the hub (e.g., when in a doctor's office waiting room). The wireless access point may be also configured to detect the presence of a patient device. In various implementations, the wireless access point may be configured to obtain identifying information of patient devices and send the information to a server. The server may be configured to use the information to create or update a profile for the patient associated with a patient device. The profile may be updated by additional information derived from the patient's interaction with the network, provider input, and/or by the patient updating their profile or inputting additional information.
The objectives of this clinical trial are to study the effects of a range of renal function on the safety and pharmacokinetics of Replagal enzyme replacement therapy in patients with Fabry Disease. Patients with clinical and genetic or biochemical evidence of Fabry Disease will be selected for this clinical trial. Sixty (60) patients will be enrolled in this clinical trial. Enrollment will be stratified based on baseline renal function as per FDA guidelines. This is an open label clinical study. Baseline evaluations will be conducted over an approximately 3 day period. Patients will receive intravenous (IV) infusions of Replagal at a dose of 0.2 mg/kg/dose every 2 weeks. Pharmacokinetic studies will be performed with the first administered dose. The safety evaluations for patients in this study will include vital signs, physical examinations, adverse event (AE) assessments, electrocardiograms (ECG), and a battery of laboratory tests including measurement of anti-Replagal antibodies. An overview of the study appears in Appendix A.
This group was composed of 15 subjects. The application of dry needling and Low-Level Laser Therapy (LLLT) turned on will be directly on the trigger point. The intervention will be administered one time.